 Nootropic Agents
"Nootropic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.
| Descriptor ID |
D018697
|
| MeSH Number(s) |
D27.505.954.427.637
|
| Concept/Terms |
Nootropic Agents- Nootropic Agents
- Agents, Nootropic
- Nootropics
- Cognitive Enhancers
- Enhancers, Cognitive
- Nootropic Drugs
- Drugs, Nootropic
|
Below are MeSH descriptors whose meaning is more general than "Nootropic Agents".
Below are MeSH descriptors whose meaning is more specific than "Nootropic Agents".
This graph shows the total number of publications written about "Nootropic Agents" by people in this website by year, and whether "Nootropic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Nootropic Agents" by people in Profiles.
-
Hall DA, Robertson EE, Leehey M, McAsey A, Ouyang B, Berry-Kravis E, O'Keefe JA. Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS). PLoS One. 2020; 15(2):e0225191.
-
Modi KK, Rangasamy SB, Dasarathi S, Roy A, Pahan K. Cinnamon Converts Poor Learning Mice to Good Learners: Implications for Memory Improvement. J Neuroimmune Pharmacol. 2016 12; 11(4):693-707.
-
Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33.
-
Rangasamy SB, Corbett GT, Roy A, Modi KK, Bennett DA, Mufson EJ, Ghosh S, Pahan K. Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2015; 47(2):385-402.
-
Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012; 54:297-335.
-
Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 01; 32(3):739-43.
-
Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, Leurgans SE. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006 Oct 10; 67(7):1268-71.
-
Karlawish JH, Casarett DJ, James BD, Xie SX, Kim SY. The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment. Neurology. 2005 May 10; 64(9):1514-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|